Seqens CDMO has unveiled plans to enhance flow chemistry capabilities at its Seqens’Lab R&D center for efficient and safe synthesis of active pharmaceutical ingredients (APIs) and intermediates.   The company says by the end of 2020, Seqens’Lab will add GMP pilot plant to its continuous bench reactors and analytical tools to increase capacity to handle difficult reactions, intermediates and APIs.   Approximately 2,800 APIs are currently marketed, 70% of which are synthetic ch...